STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
AI Summary
Eli Lilly's acquisition of AtaiBeckley for $2.8 billion marks a significant leap into the psychedelics field, aiming to bolster its neuroscience portfolio. This move underscores the growing interest in psychedelics for treating mental health disorders, particularly depression. With the potential to unlock new therapeutic avenues, this acquisition could reshape how we approach mental health treatment, signaling a major shift in pharmaceutical strategies.
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.